Business
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
Cohen and Associates is a highly respected neuropsychiatry clinic in western FloridaCohen to serve as foundational clinic in the Sarasota - Bradenton area of
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Cohen and Associates is a highly respected neuropsychiatry clinic in western FloridaCohen to serve as foundational clinic in the Sarasota - Bradenton area of FloridaAcquisition expected to be immediately accretive to revenue and EBITDAMIAMI, June 26, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. (\"HOPE\"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced the signing of a binding Letter of Intent (the \"LOI\") to purchase a 49% interest in Cohen and Associates, LLC (\"Cohen\"), founded by Dr. Rebecca Cohen. Cohen is expected to serve as a foundational clinic for HOPE in the Sarasota-Bradenton region of western Florida. \n\n \n \n \n \n \n \n\n \nCohen is one of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation (\"TMS\") as well as medication management. \nDr. Cohen is an Interventional Psychiatrist and Psychopharmacologist specializing in the treatment of mood and anxiety disorders as well as a nationally recognized expert in TMS. Her practice was established in 2014 to deliver top tier Psychiatric evaluations and comprehensive clinical care. She has expanded the scope of her practice with the addition of outstanding colleagues and technologies to deliver the most evidence-based and compassionate care in the region. Dr. Cohen's academic background spans Tufts University, Boston University, where she was recipient of the psychiatry department's Malamud Award for Excellence and Georgetown University. Dr Cohen has been honored as a Fellow of both the American Psychiatric Association and the International Clinical TMS Society.\n\"We are delighted to welcome Rebecca and her team to the HOPE family. Her extensive experience with neuroplastic therapies, combined with compassionate patient care exemplify our culture of bringing HOPE to life,\" said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics.\n\"I am thrilled to be working with HOPE at this exciting juncture in the company's evolution. Our goal will always be to deliver outstanding patient care by offering the best available treatments and individualized ca...